Repligen Corporation
Financials
Valuation Metrics
Repligen Corporation's Market Cap is $8.30B. At end of 2025 it was $9.26B. Ranked #1054 of 3,112 in US market (top 34%), #343 of 1,445 on NASDAQ (top 24%), #72 of 206 in Health Care Equipment & Services (top 35%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.30B | US#1,054/3,112 Sec#72/206 |
| Revenue | $785M | US#2,081/3,112 Sec#130/206 |
| Net Income | $42M | US#1,916/3,112 Sec#90/206 |
| Total Assets | $2.95B | US#1,807/3,112 Sec#87/206 |
| Net Assets | $2.11B | US#1,209/3,112 Sec#60/206 |
| Employees | 2,000 | US#1,115/3,112 Sec#92/206 |
| Value | ||
| P/E | 199.70x | US#2,145/3,112 Sec#110/206 |
| P/B | 3.93x | US#1,962/3,112 Sec#120/206 |
| P/S | 10.57x | US#2,680/3,112 Sec#189/206 |
| EV/EBITDA | 68.78x | US#2,401/3,112 Sec#130/206 |
| FCF Yield | 1.34% | US#2,081/3,112 Sec#132/206 |
| Profitability | ||
| ROE | 1.97% | US#2,051/3,112 Sec#105/206 |
| ROA | 1.41% | US#1,765/3,112 Sec#103/206 |
| Op. Margin | 8.32% | US#1,763/3,112 Sec#89/206 |
| Revenue Growth | 11.93% | US#1,144/3,112 Sec#79/206 |
| Earnings Growth | -66.31% | US#1,937/3,112 Sec#97/206 |
| Financial Health | ||
| Debt Ratio | 39.68% | US#450/3,112 Sec#54/206 |
| Total Debt | $691M | US#1,661/3,112 Sec#93/206 |
| FCF | $111M | US#1,628/3,112 Sec#99/206 |
| Cash | $607M | US#951/3,112 Sec#51/206 |
| Current Ratio | 9.05x | US#275/3,112 Sec#16/206 |
| Net Debt/EBITDA | 0.69x | US#900/3,112 Sec#52/206 |
| Performance | ||
| 1Y Return | 23.67% | US#1,298/3,112 Sec#85/206 |
| 1M Return | 3.27% | US#1,167/3,112 Sec#87/206 |
| From 52W High | -16.33% | US#1,486/3,112 Sec#105/206 |
| 1Y MDD | -40.28% | US#1,961/3,112 Sec#111/206 |
| Trading | ||
| Volume | 877,346 shares | US#1,593/3,112 Sec#116/206 |
| Trading Value | $127M | US#757/3,112 Sec#60/206 |
| Per Share | ||
| EPS | $0.86 | US#1,683/3,112 Sec#84/206 |
| BPS | $37.26 | US#650/3,112 Sec#45/206 |
Company Info
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.